cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.5774520
title: KiSSim: Predicting off-targets from structural similarities in the kinome

description: <strong>KiSSim: Predicting off-targets from structural similarities in the kinome</strong> <strong>Project description.</strong> KiSSim (Kinase Structural Similarity) is a novel fingerprint designed specifically for kinase pockets, allowing for similarity studies across the structurally covered kinome. The kinase fingerprint is based on the KLIFS pocket alignment, which defines 85 pocket residues for all kinase structures. This enables a residue-by-residue comparison without a computationally expensive alignment step. The pocket fingerprint encodes each pocket residue’s spatial and physicochemical properties. The spatial properties describe the residue’s position in relation to the kinase pocket center and important kinase subpockets, i.e. the hinge region, the DFG region, and the front pocket. The physicochemical properties encompass for each residue its size and pharmacophoric features, solvent exposure, and side chain orientation. Some datasets are not part of the `kissim_app` GitHub repository due to their size but can be downloaded from here to the respective kissim_app folders. <strong>Data.</strong> `20210902_KLIFS_HUMAN.tar.gz` --- save in `kissim_app/data/external/structures` `complete_SiteAlign.txt.gz` --- save in `kissim_app/data/external/sitealign` <strong>Results.</strong> `results.tar.bz2`--- save as `kissim_app/results` These are the KiSSim results: fingerprints, feature/fingerprint distances, kinase matrices, and kinase trees for structures in all (`all`), DFG-in (`dfg_in`), and DFG-out (`dfg_out`) conformation. In the case of the DFG-in conformation, we also have KiSSim runs with fingerprint subsets based on only residues that interact with certain ligands in KLIFS IFPs: Erlotinib (`dfg_in_IRE`), Imatinib (`dfg_in_STI`), Bosutinib (`dfg_in_DB8`), and Dopamapimod (`dfg_in_B96`). The folder contains README with a detailed file list. <strong>Usage.</strong> This dataset can be used to run the notebooks available on https://github.com/volkamerlab/kissim_app. Clone the kissim_app repository. Download the files provided here. If applicable, extract the archive content to the folders as indicated above and run the notebooks. <pre><code class="language-bash">cd /path/to/your/download tar -xvf results.tar.bz2 -C /path/to/kissim_app/ tar -xvf 20210902_KLIFS_HUMAN.tar.bz2 -C /path/to/kissim_app/data/external/structures/ # In case you want the raw SiteAlign data mv complete_SiteAlign.txt.gz /path/to/kissim_app/data/external/sitealign</code></pre> <strong>Citation.</strong> These datasets are part of the KiSSim publication: TBA
DOI: 10.5281/zenodo.5784199
title: Nedystoma dayi RB0472 SPAdes preassembly

description: .
DOI: 10.5281/zenodo.5784198
title: Nedystoma dayi RB0472 SPAdes preassembly

description: .
DOI: 10.5281/zenodo.5784601
title: Lagrangian Sequestration Efficiency Trajectories and Extracted Particle Metrics – 500m Y13 & Y14

description: A dataset of Lagrangian trajectories used to estimate North Atlantic sequestration efficiency and extracted metrics for the re-entrained and sequestered particles. All variables have long names and units. These files have been used for the analysis in Baker et al. ‘Biological carbon pump sequestration efficiency in the North Atlantic: a leaky or a long-term sink?’ with further information about the methodology available in the paper. Due to the size of the datasets, each DOI only contains two files. This dataset contains the 500m particles releases for the years 2008 (Y13) and 2009 (Y14).
DOI: 10.5281/zenodo.5784600
title: Lagrangian Sequestration Efficiency Trajectories and Extracted Particle Metrics – 500m Y13 & Y14

description: A dataset of Lagrangian trajectories used to estimate North Atlantic sequestration efficiency and extracted metrics for the re-entrained and sequestered particles. All variables have long names and units. These files have been used for the analysis in Baker et al. ‘Biological carbon pump sequestration efficiency in the North Atlantic: a leaky or a long-term sink?’ with further information about the methodology available in the paper. Due to the size of the datasets, each DOI only contains two files. This dataset contains the 500m particles releases for the years 2008 (Y13) and 2009 (Y14).
DOI: 10.5281/zenodo.5784619
title: Lagrangian Sequestration Efficiency Trajectories and Extracted Particle Metrics – 500m Y15 & Y16

description: A dataset of Lagrangian trajectories used to estimate North Atlantic sequestration efficiency and extracted metrics for the re-entrained and sequestered particles. All variables have long names and units. These files have been used for the analysis in Baker et al. ‘Biological carbon pump sequestration efficiency in the North Atlantic: a leaky or a long-term sink?’ with further information about the methodology available in the paper. Due to the size of the datasets, each DOI only contains two files. This dataset contains the 500m particles releases for the years 2010 (Y15) and 2011 (Y16).
DOI: 10.5281/zenodo.5784618
title: Lagrangian Sequestration Efficiency Trajectories and Extracted Particle Metrics – 500m Y15 & Y16

description: A dataset of Lagrangian trajectories used to estimate North Atlantic sequestration efficiency and extracted metrics for the re-entrained and sequestered particles. All variables have long names and units. These files have been used for the analysis in Baker et al. ‘Biological carbon pump sequestration efficiency in the North Atlantic: a leaky or a long-term sink?’ with further information about the methodology available in the paper. Due to the size of the datasets, each DOI only contains two files. This dataset contains the 500m particles releases for the years 2010 (Y15) and 2011 (Y16).
DOI: 10.5281/zenodo.5784624
title: Lagrangian Sequestration Efficiency Trajectories and Extracted Particle Metrics – 500m Y17 & Y18

description: A dataset of Lagrangian trajectories used to estimate North Atlantic sequestration efficiency and extracted metrics for the re-entrained and sequestered particles. All variables have long names and units. These files have been used for the analysis in Baker et al. ‘Biological carbon pump sequestration efficiency in the North Atlantic: a leaky or a long-term sink?’ with further information about the methodology available in the paper. Due to the size of the datasets, each DOI only contains two files. This dataset contains the 500m particles releases for the years 2012 (Y17) and 2013 (Y18).
DOI: 10.5281/zenodo.5784623
title: Lagrangian Sequestration Efficiency Trajectories and Extracted Particle Metrics – 500m Y17 & Y18

description: A dataset of Lagrangian trajectories used to estimate North Atlantic sequestration efficiency and extracted metrics for the re-entrained and sequestered particles. All variables have long names and units. These files have been used for the analysis in Baker et al. ‘Biological carbon pump sequestration efficiency in the North Atlantic: a leaky or a long-term sink?’ with further information about the methodology available in the paper. Due to the size of the datasets, each DOI only contains two files. This dataset contains the 500m particles releases for the years 2012 (Y17) and 2013 (Y18).
DOI: 10.6075/j06t0k5v
title: Southern California Narrow Cold-Frontal Rainband (NCFR) Catalogue (1995-2020)

description: Abstract: Narrow cold-frontal rainbands (NCFR) produce short-duration, high-intensity precipitation associated with flash flooding and debris flows in Southern California, including the extremely destructive 2018 Montecito event. This manuscript presents the first known catalog of NCFR events in this region during winter seasons 1995-2020. A manual approach was used to identify NCFRs in radar imagery, supported by rain gauges and atmospheric reanalysis products. In total, 94 NCFRs were observed, with an average of three landfalling events occurring per year. Propagation and impacts of these NCFRs were also investigated. Composite analyses of synoptic conditions reveal similarities across events; however, individual NCFRs exist on a spectrum of atmospheric conditions, precipitation intensity, and associated hazards. This regional record serves as a control dataset for the development of an objective identification algorithm and supports the evaluation and improvement of forecasting procedures. Methods established here are transferrable to other mid-latitude regions with limited radar coverage.
DOI: 10.6084/m9.figshare.16709632.v4
title: Anchialine animal microbial ecology

description: These datasets accompany the paper "Animal-microbe ecology in the Hawaiian anchialine ecosystem".<br>There are data files associated with the grazing experiment, diel surveys, and fatty acid analysis and accompany R code.<br>There are also files associated with the output of the PERMANOVA analysis: for both the V6 and V9 analyses, samples with analyzed at 4 "levels" of grouping samples, so there is an output file associated with each level of analysis (Level 1 is the most coarse and level 4 is the most fine).
DOI: 10.5281/zenodo.5784636
title: Coefficients for the SMACPy atmospheric correction algorithm

description: This dataset stores coefficients used by the updated Simplified Method for Atmospheric Correction - Python (SMACPy). The coefficients are used, together with meteorological data, to remove the effects of atmospheric gases and aerosols from a satellite image. Currently, this is a beta version and more updates to these coefficients may be expected in the future. Coefficients exist for various aerosol types, all defined from the equivalent 6S (10.1109/36.581987) aerosol types: BIOMA: Biomass burning plumes. CONTI: Continental aerosol. DESER: Desert dust aerosol. MARIT: Maritime aerosol, primarily sea salt. STRATO: Stratospheric aerosol. URBAN: Urban pollution aerosol. NOAER: A profile with no aerosol effects, just atmospheric gases and Rayleigh scattering. In this version the following satellites / sensors are supported: NASA Aqua / MODIS NASA Terra / MODIS Fengyun-4A / AGRI GEO-KOMPSAT-2A / AMI GOES-16 / ABI GOES-17 / ABI Himawari-8 / AHI Landsat-8 / OLI Meteosat-8 / SEVIRI (no HRV channel) Meteosat-9 / SEVIRI (no HRV channel) Meteosat-10 / SEVIRI (no HRV channel) Meteosat-11 / SEVIRI (no HRV channel) NOAA-20 / VIIRS (M and I bands) Suomi-NPP / VIIRS (M and I bands) Sentinel-2A / MSI Sentinel-2B / MSI Sentinel-3A / OLCI Sentinel-3B / OLCI Sentinel-3A / SLSTR Sentinel-3B / SLSTR
DOI: 10.5281/zenodo.5784635
title: Coefficients for the SMACPy atmospheric correction algorithm

description: This dataset stores coefficients used by the updated Simplified Method for Atmospheric Correction - Python (SMACPy). The coefficients are used, together with meteorological data, to remove the effects of atmospheric gases and aerosols from a satellite image. Currently, this is a beta version and more updates to these coefficients may be expected in the future. Coefficients exist for various aerosol types, all defined from the equivalent 6S (10.1109/36.581987) aerosol types: BIOMA: Biomass burning plumes. CONTI: Continental aerosol. DESER: Desert dust aerosol. MARIT: Maritime aerosol, primarily sea salt. STRATO: Stratospheric aerosol. URBAN: Urban pollution aerosol. NOAER: A profile with no aerosol effects, just atmospheric gases and Rayleigh scattering. In this version the following satellites / sensors are supported: NASA Aqua / MODIS NASA Terra / MODIS Fengyun-4A / AGRI GEO-KOMPSAT-2A / AMI GOES-16 / ABI GOES-17 / ABI Himawari-8 / AHI Landsat-8 / OLI Meteosat-8 / SEVIRI (no HRV channel) Meteosat-9 / SEVIRI (no HRV channel) Meteosat-10 / SEVIRI (no HRV channel) Meteosat-11 / SEVIRI (no HRV channel) NOAA-20 / VIIRS (M and I bands) Suomi-NPP / VIIRS (M and I bands) Sentinel-2A / MSI Sentinel-2B / MSI Sentinel-3A / OLCI Sentinel-3B / OLCI Sentinel-3A / SLSTR Sentinel-3B / SLSTR
DOI: 10.6084/m9.figshare.3761562.v2074
title: Online Labour Index: Measuring the Online Gig Economy for Policy and Research

description: Data repository for the data underlying the Online Labour Index. See http://ilabour.oii.ox.ac.uk online-labour-index/ for details.
DOI: 10.5281/zenodo.5784663
title: Full data for 'Experimental phase diagram of zero-bias conductance peaks in superconductor/semiconductor nanowire devices'

description: This repository contains experimental data for the following paper:<br> Experimental phase diagram of zero-bias conductance peaks in superconductor/semiconductor nanowire devices<br> Authors: Jun Chen, Peng Yu, John Stenger, Moïra Hocevar, Diana Car, Sébastien R. Plissard, Erik P.A.M. Bakkers, Tudor D. Stanescu, Sergey M. Frolov Content of this repository: Readme file. /RawData/<br> Original data obtained at the time of measurement for devices 1014-841 and 1115A4. ZBP phase diagram data was measured on device 1014-841; Hard gap data was measured on device 1115A4 /Measurement notes/<br> All the measurement data was summarized in powerpoints, catagorized by the name of the device. /Data of paper figures/<br> All the organized data files for the figures in the main text and supplementary information. Data file types:<br> data_NNN.dat - the original data file obtained at the time of the experiment<br> dataNNN.py - the original QTLab data acquisition script saved with data<br> data_NNN.set - settings of measurement instruments at the time of measurement<br> data_NNN.meta - auxillary file necessary for plotting data using SpyView (see below) <br> data_NNN.MTX - a simple 2D/3D matrix format developed for Spyview NNN stands for dataset number, automatically indexed by QTLab How to plot data: 1) Spyview - a free data plotting program written by Gary Steele Data in this repository can be simply dropped into Spyview for plotting. Spyview also produces and can read .mtx files which are available for some of the data in this repository. https://nsweb.tn.tudelft.nl/~gsteele/spyview/ <br> 2) QTPlot - a Python plotter written by Ruben van Gulik Data in this repository can be directly opened with QTPlot, which will read axis labels. https://github.com/Rubenknex/qtplot Note: requires PyQT4
DOI: 10.5281/zenodo.5784662
title: Full data for 'Experimental phase diagram of zero-bias conductance peaks in superconductor/semiconductor nanowire devices'

description: This repository contains experimental data for the following paper:<br> Experimental phase diagram of zero-bias conductance peaks in superconductor/semiconductor nanowire devices<br> Authors: Jun Chen, Peng Yu, John Stenger, Moïra Hocevar, Diana Car, Sébastien R. Plissard, Erik P.A.M. Bakkers, Tudor D. Stanescu, Sergey M. Frolov Content of this repository: Readme file. /RawData/<br> Original data obtained at the time of measurement for devices 1014-841 and 1115A4. ZBP phase diagram data was measured on device 1014-841; Hard gap data was measured on device 1115A4 /Measurement notes/<br> All the measurement data was summarized in powerpoints, catagorized by the name of the device. /Data of paper figures/<br> All the organized data files for the figures in the main text and supplementary information. Data file types:<br> data_NNN.dat - the original data file obtained at the time of the experiment<br> dataNNN.py - the original QTLab data acquisition script saved with data<br> data_NNN.set - settings of measurement instruments at the time of measurement<br> data_NNN.meta - auxillary file necessary for plotting data using SpyView (see below) <br> data_NNN.MTX - a simple 2D/3D matrix format developed for Spyview NNN stands for dataset number, automatically indexed by QTLab How to plot data: 1) Spyview - a free data plotting program written by Gary Steele Data in this repository can be simply dropped into Spyview for plotting. Spyview also produces and can read .mtx files which are available for some of the data in this repository. https://nsweb.tn.tudelft.nl/~gsteele/spyview/ <br> 2) QTPlot - a Python plotter written by Ruben van Gulik Data in this repository can be directly opened with QTPlot, which will read axis labels. https://github.com/Rubenknex/qtplot Note: requires PyQT4
DOI: 10.5517/ccdc.csd.cc1zrswd
title: CCDC 1840125: Experimental Crystal Structure Determination

description: Related Article: han bo|2018|CSD Communication|||
description: Related Article: Bo Han, Miaomiao Zhang, Hongmei Jiao, Haojie Ma, Jijiang Wang, Yuqi Zhang|2021|RSC Advances|11|39934|doi:10.1039/D1RA07266H
DOI: 10.25934/00005107
title: Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.

description: Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The objective of the current study is to assess the safety, tolerability, and pharmacokinetics, of this formulation in children aged 4 to 16 years.
DOI: 10.25934/00005108
title: Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy

description: Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The objective of the current study is to assess the safety, tolerability, and pharmacokinetics, of this formulation in children aged 1 month to 4 years.
DOI: 10.25934/00005112
title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

description: Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial. The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine. Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).
DOI: 10.25934/00005113
title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

description: The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless leg syndrome (RLS). Additional objectives are to investigate the safety and tolerability of rotigotine. The primary variables are the absolute change from Baseline in the International Restless Legs Severity Scale (IRLS) sum score and Clinical Global Impression-Global Improvement (CGI) Item 1 (severity of illness) score at the end of the Maintenance Period. Subjects will be randomized to receive either placebo, 2.25, 4.5 or 6.75 mg/day rotigotine in a 1:1:1:1 (active:placebo) fashion. Approximately 450 subjects will be enrolled in this trial, participating at approximately 50 sites. The maximum duration of the trial is approximately 8 months (3-week Titration Period, 6-month Maintenance Period, 7-day Taper Period, and 30-day Safety Follow-Up Period). Subjects who complete the 6-month Maintenance Period will be eligible to participate in an open-label extension trial. Subjects who do not complete the 6-month Maintenance Period or who choose not to participate in the open-label extension trial will complete a 3-day Safety Follow-Up Period. Two different patch sizes will be used (5 and 10 cm2). Active patches will contain either 2.25mg (5cm2) or 4.5mg (10cm2) of rotigotine.
DOI: 10.25934/00005129
title: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy

description: This trial was conducted at about 50 sites in Europe and has been clinically completed. Patients had symptoms of painful diabetic neuropathy for 6 months up to 5 years with an optimized diabetic control and at least moderate pain. Patients were not eligible with other chronic pain or any other medical or psychiatric condition, that would have jeopardized or compromised the patient's ability to participate in the trial. After a 2-week run-in phase patients were randomly assigned to one of three treatment arms. All patients who had completed the 6-week titration phase to reach their target dose entered a 12-week maintenance phase. At the end of the maintenance phase, subjects were offered the option of entering the open-label, follow-on trial. The change in pain was measured daily as well as interference of pain with sleep and general activity.
DOI: 10.25934/00005128
title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety OF 200, 400, AND 600 mg/Day SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

description: This phase 2b trial is being conducted at approximately 60 sites in the US to investigate whether lacosamide (SPM 927) at different doses reduces pain in subjects with diabetic neuropathy. Approximately 360 subjects will be randomized to placebo or one of three doses of lacosamide. To qualify for this trial, subjects with symptoms of painful distal diabetic neuropathy ranging in duration from 6 months to 5 years must have an average pain intensity of ≥4 on an 11-point Likert scale (0-10 scale) during the 7 day period prior to start of treatment. To determine what effect lacosamide has on diabetic neuropathic pain, subjects will use a diary to record their daily pain intensity (morning and evening), pain interference with sleep (morning) and activity (evening). Use of rescue medication (acetaminophen) and subjects' quality of life will be investigated. In addition, safety and tolerability of the different doses of lacosamide will be investigated.
DOI: 10.25934/00005105
title: A multi-center, multinational, Phase 3, randomized, double-blind, parallel
group, placebo-controlled trial of the efficacy and safety of rotigotine CDS patch (2 target
doses) in subjects with advanced-stage, idiopathic Parkinsonï¿½s disease who are not well
controlled on levodopa

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00005123
title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD

description: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.